Literature DB >> 19818366

Modulation of sensory nerve function and the cough reflex: understanding disease pathogenesis.

Julie Nasra1, Maria G Belvisi.   

Abstract

To cough is a protective defence mechanism that is vital to remove foreign material and secretions from the airways and which in the normal state serves its function appropriately. Modulation of the cough reflex pathway in disease can lead to inappropriate chronic coughing and an augmented cough response. Chronic cough is a symptom that can present in conjunction with a number of diseases including chronic obstructive pulmonary disease (COPD) and asthma, although often the cause of chronic cough may be unknown. As current treatments for cough have proved to exhibit little efficacy and are largely ineffective, there is a need to develop novel, efficacious and safe antitussive therapies. The underlying mechanisms of the cough reflex are complex and involve a network of events, which are not fully understood. It is accepted that the cough reflex is initiated following activation of airway sensory nerves. Therefore, in the hope of identifying novel antitussives, much research has focused on understanding the neural mechanisms of cough provocation. Experimentally this has been undertaken using chemical or mechanical tussive stimuli in conjunction with animal models of cough and clinical cough assessments. This review will discuss the neural mechanisms involved in the cough, changes that occur under pathophysiological conditions and and how current research may lead to novel therapeutic opportunities for the treatment of cough.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19818366     DOI: 10.1016/j.pharmthera.2009.09.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  18 in total

1.  The efficacy of a NOP1 agonist (SCH486757) in subacute cough.

Authors:  Ashley Woodcock; Robbie L McLeod; Jonathan Sadeh; Jaclyn A Smith
Journal:  Lung       Date:  2010-01       Impact factor: 2.584

2.  Inhibition of airway hyper-responsiveness by TRPV1 antagonists (SB-705498 and PF-04065463) in the unanaesthetized, ovalbumin-sensitized guinea pig.

Authors:  I Delescluse; H Mace; J J Adcock
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 3.  TRP channel antagonists as potential antitussives.

Authors:  Megan S Grace; Eric Dubuis; Mark A Birrell; Maria G Belvisi
Journal:  Lung       Date:  2011-10-02       Impact factor: 2.584

Review 4.  Targeting TRP channels for chronic cough: from bench to bedside.

Authors:  Sara J Bonvini; Mark A Birrell; Jaclyn A Smith; Maria G Belvisi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-10       Impact factor: 3.000

5.  Transient receptor potential channels mediate the tussive response to prostaglandin E2 and bradykinin.

Authors:  Megan Grace; Mark A Birrell; Eric Dubuis; Sarah A Maher; Maria G Belvisi
Journal:  Thorax       Date:  2012-06-12       Impact factor: 9.139

6.  Cough response to isocapnic hyperpnoea of dry air and hypertonic saline are interrelated.

Authors:  Minna Purokivi; Heikki Koskela; John D Brannan; Kirsi Kontra
Journal:  Cough       Date:  2011-10-14

7.  Levodropropizine for treating cough in adult and children: a meta-analysis of published studies.

Authors:  Alessandro Zanasi; Luigi Lanata; Giovanni Fontana; Federico Saibene; Peter Dicpinigaitis; Francesco De Blasio
Journal:  Multidiscip Respir Med       Date:  2015-05-31

8.  Capability of hypertonic saline cough provocation test to predict the response to inhaled corticosteroids in chronic cough: a prospective, open-label study.

Authors:  Heikki O Koskela; Minna K Purokivi
Journal:  Cough       Date:  2013-05-20

9.  Molecular signaling and targets from itch: lessons for cough.

Authors:  Pamela Colleen Lavinka; Xingzhong Dong
Journal:  Cough       Date:  2013-03-06

Review 10.  TRP Channels in Respiratory Pathophysiology: the Role of Oxidative, Chemical Irritant and Temperature Stimuli.

Authors:  Alexander V Zholos
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.